# Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer

> **NCT03281382** · PHASE1 · COMPLETED · sponsor: **Henry Ford Health System** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** Ad5-yCD/mutTKSR39rep-hIL12

## Key facts

- **NCT ID:** NCT03281382
- **Lead sponsor:** Henry Ford Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2019-05-28
- **Final completion:** 2019-05-28
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03281382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03281382, "Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03281382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*